Valeant to buy hepatitis C therapy for $113.5M

InterMune has agreed to sell the US and Canadian rights to its hepatitis C therapy Infergen to Valeant Pharmaceuticals for $113.5 million and performance payments of up to $22.5 million. Valeant will gain about $6.5 million in inventory from the Brisbane, CA-based InterMune and will hire 50 members of their sales and marketing staff. InterMune says the deal will reduce its operating costs by $50 million and allow it to focus more on a separate hepatitis C drug and another therapy for lung scarring. Infergen posted $22 million in sales last year.

- read this AP report for more information on the deal

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.